As spot­light trains on bio­phar­ma di­ver­si­ty, most com­pa­nies kept their C-suites ex­act­ly the same in 2020 — re­port

The past year has cast a harsh spot­light on the bio­phar­ma in­dus­try’s lack of di­ver­si­ty. And though most com­pa­nies list di­ver­si­ty and in­clu­sion as one of their key val­ues, a whop­ping 67% of com­pa­nies saw lit­tle or no change in rep­re­sen­ta­tion by race or eth­nic­i­ty at the ex­ec­u­tive lev­el, ac­cord­ing to a re­cent BIO sur­vey.

As part of its sec­ond an­nu­al di­ver­si­ty re­port, BIO part­nered with Co­qual (for­mer­ly known as Cen­ter for Tal­ent In­no­va­tion) to sur­vey 100 com­pa­nies from Oc­to­ber to De­cem­ber 2020. They re­ceived or­ga­ni­za­tion-lev­el di­ver­si­ty da­ta from 18 com­pa­nies, and ex­ec­u­tive-lev­el di­ver­si­ty da­ta from 16. Sev­en­ty per­cent of re­spon­dents list­ed D&I as one of their stat­ed val­ues, BIO said. But on­ly 13% ac­tu­al­ly in­creased rep­re­sen­ta­tion for ex­ec­u­tives of col­or by at least 5%.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA